Intramuscular Ketamine for Suicidal Ideation

A randomised, double-blind, crossover pilot study planned to test whether specific EEG changes correlate with reduction in suicidal ideation following a single IM ketamine dose (0.5 mg/kg) compared with placebo in inpatients with clinically significant SI.

Primary aims were to identify EEG biomarkers associated with anti-suicidal response and to assess the acute effectiveness of IM ketamine on suicidal ideation; outcomes included EEG measures and standard clinical scales (MADRS item 10, C-SSRS).